Contribution of Intrinsic Reactivity of the HIV-1 Envelope Glycoproteins to CD4-Independent Infection and Global Inhibitor Sensitivity

English version České info

Human immunodeficiency virus (HIV-1) enters cells following sequential activation of the high-potential-energy viral envelope glycoprotein trimer by target cell CD4 and coreceptor. HIV-1 variants differ in their requirements for CD4; viruses that can infect coreceptor-expressing cells that lack CD4 have been generated in the laboratory. These CD4-independent HIV-1 variants are sensitive to neutralization by multiple antibodies that recognize different envelope glycoprotein epitopes. The mechanisms underlying CD4 independence, global sensitivity to neutralization and the association between them are still unclear. By studying HIV-1 variants that differ in requirements for CD4, we investigated the contribution of CD4 binding to virus entry. CD4 engagement exposes the coreceptor-binding site and increases the “intrinsic reactivity” of the envelope glycoproteins; intrinsic reactivity describes the propensity of the envelope glycoproteins to negotiate transitions to lower-energy states upon stimulation. Coreceptor-binding site exposure and increased intrinsic reactivity promote formation/exposure of the HR1 coiled coil on the gp41 transmembrane glycoprotein and allow virus entry upon coreceptor binding. Intrinsic reactivity also dictates the global sensitivity of HIV-1 to perturbations such as exposure to cold and the binding of antibodies and small molecules. Accordingly, CD4 independence of HIV-1 was accompanied by increased susceptibility to inactivation by these factors. We investigated the role of intrinsic reactivity in determining the sensitivity of primary HIV-1 isolates to inhibition. Relative to the more common neutralization-resistant (“Tier 2-like”) viruses, globally sensitive (“Tier 1”) viruses exhibited increased intrinsic reactivity, i.e., were inactivated more efficiently by cold exposure or by a given level of antibody binding to the envelope glycoprotein trimer. Virus sensitivity to neutralization was dictated both by the efficiency of inhibitor/antibody binding to the envelope glycoprotein trimer and by envelope glycoprotein reactivity to the inhibitor/antibody binding event. Quantitative differences in intrinsic reactivity contribute to HIV-1 strain variability in global susceptibility to neutralization and explain the long-observed relationship between increased inhibitor sensitivity and decreased entry requirements for target cell CD4.

Vyšlo v časopise: Contribution of Intrinsic Reactivity of the HIV-1 Envelope Glycoproteins to CD4-Independent Infection and Global Inhibitor Sensitivity. PLoS Pathog 7(6): e32767. doi:10.1371/journal.ppat.1002101
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002101

Souhrn

Zdroje

1. WyattRSodroskiJ 1998 The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 1884 1888

2. LiuJBartesaghiABorgniaMJSapiroGSubramaniamS 2008 Molecular architecture of native HIV-1 gp120 trimers. Nature 455 109 113

3. MyszkaDGSweetRWHensleyPBrigham-BurkeMKwongPD 2000 Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 97 9026 9031

4. AllanJS 1991 Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science 252 1322 1323

5. AllanJSStraussJBuckDW 1990 Enhancement of SIV infection with soluble receptor molecules. Science 247 1084 1088

6. DalgleishAGBeverleyPCClaphamPRCrawfordDHGreavesMF 1984 The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 763 767

7. KlatzmannDChampagneEChamaretSGruestJGuetardD 1984 T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312 767 768

8. RayNDomsRW 2006 HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 303 97 120

9. BergerEAMurphyPMFarberJM 1999 Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17 657 700

10. ChanDCChutkowskiCTKimPS 1998 Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 95 15613 15617

11. TanKLiuJWangJShenSLuM 1997 Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94 12303 12308

12. WildCTShugarsDCGreenwellTKMcDanalCBMatthewsTJ 1994 Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91 9770 9774

13. KowalskiMPotzJBasiripourLDorfmanTGohWC 1987 Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237 1351 1355

14. FreedEOMyersDJRisserR 1990 Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci U S A 87 4650 4654

15. BoschMLEarlPLFargnoliKPicciafuocoSGiombiniF 1989 Identification of the fusion peptide of primate immunodeficiency viruses. Science 244 694 697

16. ChanDCFassDBergerJMKimPS 1997 Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 263 273

17. WeissenhornWDessenAHarrisonSCSkehelJJWileyDC 1997 Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 426 430

18. GorryPRTaylorJHolmGHMehleAMorganT 2002 Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol 76 6277 6292

19. KolchinskyPMirzabekovTFarzanMKiprilovECayabyabM 1999 Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 73 8120 8126

20. HoffmanTLLaBrancheCCZhangWCanzianiGRobinsonJ 1999 Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A 96 6359 6364

21. DumonceauxJNisoleSChanelCQuivetLAmaraA 1998 Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 72 512 519

22. TaylorBMFoulkeJSFlinkoRHerediaADeVicoA 2008 An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. J Virol 82 5460 5471

23. XiaoPUsamiOSuzukiYLingHShimizuN 2008 Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4. AIDS 22 1749 1757

24. ZerhouniBNelsonJASahaK 2004 Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes. J Virol 78 1243 1255

25. BhattacharyaJPetersPJClaphamPR 2003 CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS 17 Suppl 4 S35 43

26. EdingerALMankowskiJLDoranzBJMarguliesBJLeeB 1997 CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci U S A 94 14742 14747

27. ReevesJDDomsRW 2002 Human immunodeficiency virus type 2. J Gen Virol 83 1253 1265

28. ReevesJDHibbittsSSimmonsGMcKnightAAzevedo-PereiraJM 1999 Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 73 7795 7804

29. LaBrancheCCHoffmanTLRomanoJHaggartyBSEdwardsTG 1999 Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol 73 10310 10319

30. EdwardsTGWyssSReevesJDZolla-PaznerSHoxieJA 2002 Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 76 2683 2691

31. KolchinskyPKiprilovESodroskiJ 2001 Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 75 2041 2050

32. ZhangPFBoumaPParkEJMargolickJBRobinsonJE 2002 A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 76 644 655

33. ThomasERShottonCWeissRAClaphamPRMcKnightA 2003 CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 17 291 300

34. PufferBAPohlmannSEdingerALCarlinDSanchezMD 2002 CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 76 2595 2605

35. Cheng-MayerCBrownAHarouseJLuciwPAMayerAJ 1999 Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 73 5294 5300

36. MoHStamatatosLIpJEBarbasCFParrenPW 1997 Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. J Virol 71 6869 6874

37. ParkEJVujcicLKAnandRTheodoreTSQuinnanGVJr 1998 Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 72 7099 7107

38. PugachPKuhmannSETaylorJMarozsanAJSnyderA 2004 The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321 8 22

39. O'RourkeSMSchweighardtBScottWGWrinTFonsecaDP 2009 Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J Virol 83 7728 7738

40. O'RourkeSMSchweighardtBPhungPFonsecaDPTerryK 2005 Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol 84 11200 11209

41. WrinTLohTPVennariJCSchuitemakerHNunbergJH 1995 Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 69 39 48

42. CayabyabMKarlssonGBEtemad-MoghadamBAHofmannWSteenbekeT 1999 Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J Virol 73 976 984

43. KolchinskyPKiprilovEBartleyPRubinsteinRSodroskiJ 2001 Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol 75 3435 3443

44. JohnsonWEMorganJReitterJPufferBACzajakS 2002 A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol 76 2075 2086

45. XiangSHFarzanMSiZMadaniNWangL 2005 Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. J Virol 79 6068 6077

46. HuangCCLamSNAcharyaPTangMXiangSH 2007 Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317 1930 1934

47. HaimHSiZMadaniNWangLCourterJR 2009 Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog 5 e1000360

48. TrkolaAPurtscherMMusterTBallaunCBuchacherA 1996 Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70 1100 1108

49. ThaliMMooreJPFurmanCCharlesMHoDD 1993 Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67 3978 3988

50. WalkerLMPhogatSKChan-HuiPYWagnerDPhungP 2009 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 285 289

51. WuLGerardNPWyattRChoeHParolinC 1996 CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384 179 183

52. TrkolaADragicTArthosJBinleyJMOlsonWC 1996 CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384 184 187

53. SiZMadaniNCoxJMChrumaJJKleinJC 2004 Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A 101 5036 5041

54. FurutaRAWildCTWengYWeissCD 1998 Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 5 276 279

55. HeYVassellRZaitsevaMNguyenNYangZ 2003 Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 77 1666 1671

56. RowellJFStanhopePESilicianoRF 1995 Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol 155 473 488

57. Berlioz-TorrentCShacklettBLErdtmannLDelamarreLBouchaertI 1999 Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 73 1350 1361

58. KassaAMadaniNSchonAHaimHFinziA 2009 Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol 83 8364 8378

59. XiangSHKwongPDGuptaRRizzutoCDCasperDJ 2002 Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 76 9888 9899

60. KwongPDDoyleMLCasperDJCicalaCLeavittSA 2002 HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 678 682

61. ChenLKwonYDZhouTWuXO'DellS 2009 Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326 1123 1127

62. KangSMQuanFSHuangCGuoLYeL 2005 Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology 331 20 32

63. KassaAFinziAPanceraMCourterJRSmithAB3rd 2009 Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation. J Virol 83 4476 4488

64. FinziAXiangSHPachecoBWangLHaightJ 2010 Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 37 656 667

65. MascolaJRSnyderSWWeislowOSBelaySMBelsheRB 1996 Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173 340 348

66. MooreJPCaoYQingLSattentauQJPyatiJ 1995 Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69 101 109

67. SiZCayabyabMSodroskiJ 2001 Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. J Virol 75 4208 4218

68. HarouseJMGettieATanRCBlanchardJCheng-MayerC 1999 Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284 816 819

69. KlassePJMcKeatingJASchuttenMReitzMSJrRobert-GuroffM 1993 An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(–>Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Virology 196 332 337

70. ParkEJGornyMKZolla-PaznerSQuinnanGVJr 2000 A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J Virol 74 4183 4191

71. MascolaJRD'SouzaPGilbertPHahnBHHaigwoodNL 2005 Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79 10103 10107

72. SeamanMSLeblancDFGrandpreLEBartmanMTMontefioriDC 2007 Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 367 175 186

73. SeamanMSJanesHHawkinsNGrandpreLEDevoyC 2010 Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84 1439 1452

74. DeckerJMBibollet-RucheFWeiXWangSLevyDN 2005 Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201 1407 1419

75. LabrijnAFPoignardPRajaAZwickMBDelgadoK 2003 Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77 10557 10565

76. PrivalovPL 1990 Cold denaturation of proteins. Crit Rev Biochem Mol Biol 25 281 305

77. SchentenDMarconLKarlssonGBParolinCKodamaT 1999 Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells. J Virol 73 5373 5380

78. WhiteTABartesaghiABorgniaMJMeyersonJRde la CruzMJ 2010 Molecular Architectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact Viruses: Strain-Dependent Variation in Quaternary Structure. PLoS Pathog 6 e1001249

79. BurtonDRPyatiJKoduriRSharpSJThorntonGB 1994 Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 1024 1027

80. ZhouTXuLDeyBHessellAJVan RykD 2007 Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 732 737

81. RajaAVenturiMKwongPSodroskiJ 2003 CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J Virol 77 713 718

82. PosnerMRHideshimaTCannonTMukherjeeMMayerKH 1991 An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 146 4325 4332

83. MoorePLCrooksETPorterLZhuPCayananCS 2006 Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80 2515 2528

84. MusterTSteindlFPurtscherMTrkolaAKlimaA 1993 A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67 6642 6647

85. RobenPMooreJPThaliMSodroskiJBarbasCF3rd 1994 Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68 4821 4828

86. EarlPLBroderCCDomsRWMossB 1997 Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 71 2674 2684

87. KorberBFoleyBKuikenCPillaiSSodroskiJ 1998 Human Retroviruses and AIDS. Los Alamos Los Alamos Natl Lab

88. YangXTomovVKurtevaSWangLRenX 2004 Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J Virol 78 12975 12986

89. MadaniNSchönAPrinciottoAMLalondeJMCourterJR 2008 Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16 1689 1701

90. SullivanNSunYLiJHofmannWSodroskiJ 1995 Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 69 4413 4422

91. HeckmanKLPeaseLR 2007 Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc 2 924 932

92. KwongPDWyattRDesjardinsERobinsonJCulpJS 1999 Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J Biol Chem 274 4115 4123

93. LiMGaoFMascolaJRStamatatosLPolonisVR 2005 Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 10108 10125

94. RhoHMPoieszBRuscettiFWGalloRC 1981 Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology 112 355 360